How endobronchial valves change oxygen use during everyday activities
Change in Task-related Oxygen Uptake After Bronchoscopic Lung Volume Reduction With Endobronchial Valves
This will see if endobronchial valve treatment helps people with severe emphysema use less oxygen and feel less breathless when doing daily tasks.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 20 (estimated) |
| Sex | All |
| Sponsor | University Medical Center Groningen Academic / other |
| Locations | 1 site (Groningen) |
| Trial ID | NCT06702072 on ClinicalTrials.gov |
What this trial studies
This is an observational study of patients scheduled for bronchoscopic lung volume reduction with Pulmonx Zephyr endobronchial valves. Researchers will measure oxygen uptake (VO2) and carbon dioxide production (VCO2) with a portable metabolic device while participants perform typical activities of daily living before and after EBV treatment. The primary focus is to compare the metabolic load and symptom perception during ADLs rather than laboratory walk tests. Results will show whether physiological effort during real-world tasks changes after valve placement.
Who should consider this trial
Good fit: Ideal candidates are patients with severe emphysema who are scheduled for Pulmonx Zephyr endobronchial valve placement, can perform ADLs without long-term oxygen therapy, and can give informed consent.
Not a fit: Patients who require long-term oxygen therapy during ADLs or who are not eligible for EBV placement are unlikely to benefit from this protocol.
Why it matters
Potential benefit: If successful, the treatment could reduce metabolic load and breathlessness during daily activities, making routine tasks easier for patients.
How similar studies have performed: Previous EBV research has shown improvements in exercise capacity by 6-minute walk tests and patient reports of easier ADLs, but the metabolic load during real-world ADLs has not been measured before.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patient is scheduled for a bronchoscopic lung volume treatment using Pulmonx Zephyr Endobronchial Valves; 2. Patient read, understood and signed the Informed Consent Form. Exclusion Criteria: 1\) Patients who cannot perform ADL activities without the use of Long Term Oxygen Therapy (LTOT).
Where this trial is running
Groningen
- University Medical Center Groningen — Groningen, Netherlands (Recruiting)
Study contacts
- Principal investigator: Dirk-Jan Slebos, MD PHD — University Medical Center Groningen
- Study coordinator: Jorine E Hartman, PhD
- Email: j.hartman@umcg.nl
- Phone: 0031503619194
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.